Amgen, the world’s largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.
Copenhagen-headquartered Nuevolution said its board unanimously recommended Amgen’s cash offer of 32.5 Swedish crowns per share, a premium of 168.6% to Nuevolution’s closing price on Tuesday.
Nuevolution has a patent protected drug research platform to identify small-molecule drug candidates to be taken as pills against cancer and inflammatory diseases.
Most new drugs in these therapeutic areas are currently based on large proteins made from genetically modified living cells which need to be injected and are expensive to manufacture.
Nuevolution has partnered with pharma majors including Novartis, Johnson & Johnson, Boehringer Ingelheim, GlaxoSmithKline and Merck & Co, according to its website.
The company was founded in 2011 and employs 40 full-time professionals.
Amgen, which is grappling with competition to its new migraine treatment Aimovig and cholesterol fighter Repatha, said it had collaborated with Nuevolution since 2016 and that it had exercised opt-in rights for two cancer treatment approaches that have emerged from the alliance.
At 0850 GMT, Nuevolution shares were up 165% at 32.1 crowns
By Philip George, Ludwig Burger and Jacob Gronholt-Pedersen
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
